Skip to main content

Table 1 Clinico-pathological characteristics of patient cohort

From: Differential pattern and prognostic significance of CD4+, FOXP3+ and IL-17+tumor infiltrating lymphocytes in ductal and lobular breast cancers

Feature   Frequency n (%)
   Ductal carcinoma (n = 894) Lobular carcinoma (n = 164)
pT stage pT1 369 (41.3) 52 (31.7)
  pT2 475 (53.1) 90 (54.9)
  pT3 50 (5.6) 22 (13.4)
pN stage pN0 485 (54.3) 90 (54.9)
  pN1 340 (38.0) 67 (40.8)
  pN2 69 (7.7) 7 (4.3)
Clinical stage IA 254 (28.4) 39 (23.8)
  IIA 325 (36.4) 54 (32.9)
  IIB 211 (23.6) 42 (25.6)
  IIIA 104 (11.6) 29 (17.7)
BRE grade G1 181 (20.4) 24 (14.7)
  G2 372 (41.9) 118 (72.4)
  G3 334 (37.7) 21 (12.9)
ER status Negative 200 (23.7) 22 (14.4)
  Positive 645 (76.3) 131 (85.6)
PR status Negative 346 (52.6) 65 (54.6)
  Positive 312 (47.4) 54 (45.4)
Her-2/neu 0 and 1+ 680 (83.1) 130 (94.2)
  2+ and 3+ 138 (16.9) 8 (5.8)
Molecular Subtypes Luminal A 160 (40.1) 30 (48.4)
  Luminal B 7 (1.8) 0 (0.0)
  Her2/neu 64 (16.0) 3 (4.8)
  Triple Negative 168 (42.1) 29 (46.8)
Disease-specific survival death from breast cancer 72 (8.7) 9 (5.8)
  Censored 760 (91.3) 145 (94.2)
  5-year (95%CI) 94.0 (92-96) 97.0 (92-99)
Overall survival Death 172 (19.4) 34 (21.3)
  Censored 714 (80.6) 126 (78.7)
  5-year (95%CI) 85.6 (83-88) 87.8 (81-92)
Age at diagnosis (y) median 62 64
  Minimum-maximum 28-94 38-90
\